RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD
Life Science Alliance · 2025
DOI: 10.26508/lsa.202402757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2025. Verfasst von Christopher P Webster und 16 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, U…. Hauptthemen laut MEDLINE: C9orf72 Protein, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, European Research Council, Alzheimer’s Research UK.
Abstract (Originalsprache)
A G4C2 hexanucleotide repeat expansion in C9orf72 is the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD). Bidirectional transcription and subsequent repeat-associated non-AUG (RAN) translation of sense and antisense transcripts leads to the formation of five dipeptide repeat (DPR) proteins. These DPRs are toxic in a wide range of cell and animal models. Therefore, decreasing RAN-DPRs may be of therapeutic benefit in the context of C9ALS/FTD. In this study, we found that C9ALS/FTD patients have reduced expression of the AAA+ family members RuvBL1 and RuvBL2, which have both been implicated in aggregate clearance. We report that overexpression of RuvBL1, but to a greater extent RuvBL2, reduced C9orf72-associated DPRs in a range of in vitro systems including cell lines, primary neurons from the C9-500 transgenic mouse model, and patient-derived iPSC motor neurons. In vivo, we further demonstrated that RuvBL2 overexpression and consequent DPR reduction in our Drosophila model was sufficient to rescue a number of DPR-related motor phenotypes. Thus, modulating RuvBL levels to reduce DPRs may be of therapeutic potential in C9ALS/FTD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK c.p.webster@sheffield.ac.uk.
- Neuroscience Institute, University of Sheffield, Sheffield, UK.
- Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK.
- Healthy Lifespan Institute (HELSI), University of Sheffield, Sheffield, UK.
- Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK m.azzouz@sheffield.ac.uk.
- Gene Therapy Innovation and Manufacturing Centre (GTIMC), Division of Neuroscience, University of Sheffield, Sheffield, UK.
ORCID-Profile: Christopher P Webster, Bradley Hall, Dana Dauletalina, Ya-Hui Lin, Ergita Kyrgiou-Balli, Laura Ferraiuolo, Kurt J De Vos, Guillaume M Hautbergue, Pamela J Shaw, Ryan Jh West, Mimoun Azzouz
Förderung
- Medical Research Council
- European Research Council
- Alzheimer’s Research UK
- Innovative Medicines Initiative 2 Joint Undertaking
- European Federation of Pharmaceutical Industries and Associations
- EU Joint Programme – Neurodegenerative Disease Research
- EC | European Research Council
- MRC DPFS Award
Zitieren
APA
Webster, C. P., Hall, B., Crossley, O. M., Dauletalina, D., King, M., Lin, Y. H., Castelli, L. M., Yang, Z. L., Coldicott, I., Kyrgiou-Balli, E., Higginbottom, A., Ferraiuolo, L., De Vos, K. J., Hautbergue, G. M., Shaw, P. J., West, R. J., & Azzouz, M. (2025). RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD. Life Science Alliance. https://doi.org/10.26508/lsa.202402757
Vancouver
Webster CP, Hall B, Crossley OM, Dauletalina D, King M, Lin YH, et al. RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD. Life Science Alliance. 2025. doi:10.26508/lsa.202402757
BibTeX
@article{Webster2025,
author = {Webster, Christopher P and Hall, Bradley and Crossley, Olivia M and Dauletalina, Dana and King, Marianne and Lin, Ya-Hui and Castelli, Lydia M and Yang, Zih-Liang and Coldicott, Ian and Kyrgiou-Balli, Ergita and Higginbottom, Adrian and Ferraiuolo, Laura and De Vos, Kurt J and Hautbergue, Guillaume M and Shaw, Pamela J and West, Ryan Jh and Azzouz, Mimoun},
title = {RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD},
journal = {Life Science Alliance},
year = {2025},
doi = {10.26508/lsa.202402757}
}
EUVIMED